An open‐label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics and pharmacodynamics

Publisher： John Wiley & Sons Inc

E-ISSN： 1552-4604|55|12|1395-1405

ISSN： 0091-2700

Source： JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol.55, Iss.12, 2015-12, pp. : 1395-1405

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacokinetics of serelaxin in patients with hepatic impairment: a single‐dose, open‐label, parallel group study

By  

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 79, Iss. 6, 2015-06 ,pp. : 937-945

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase 1, open‐label, dose escalation, safety, and pharmacokinetics study of ME‐344 as a single agent in patients with refractory solid tumors

By  

CANCER, Vol. 121, Iss. 7, 2015-04 ,pp. : 1056-1063

John Wiley & Sons Inc

Access to resources Recommend Favorite

Population pharmacokinetics of edoxaban and its main metabolite in a dedicated renal impairment study

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 91-2700, Iss. 11, 2015-11 ,pp. : 1268-1279

John Wiley & Sons Inc

Access to resources Recommend Favorite

Population pharmacokinetics of edoxaban and its main metabolite in a dedicated renal impairment study

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 55, Iss. 11, 2015-11 ,pp. : 1268-1279

John Wiley & Sons Inc

Access to resources Recommend Favorite

Randomized open‐label crossover assessment of Prograf vs Advagraf on immunosuppressant pharmacokinetics and pharmacodynamics in simultaneous pancreas‐kidney patients

By  

CLINICAL TRANSPLANTATION (ELECTRONIC), Vol. 32, Iss. 2, 2018-02 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite